27-Hydroxycholesterol stimulates cell proliferation and resistance to docetaxel-induced apoptosis in prostate epithelial cells

详细信息    查看全文

• 作者：Shaneabbas Raza ; Megan Meyer ; Jared Schommer ; Kimberly D. P. Hammer…
• 关键词：27 ; Hydroxycholesterol ; Androgen receptor ; Proliferation ; Prostate cancer ; Benign prostatic hyperplasia
• 刊名：Medical Oncology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：33
• 期：2
• 全文大小：1,186 KB
• 参考文献：1.Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17:241–6.CrossRef PubMed
  2.Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006;13:158–68.PubMed
  3.Chokkalingam AP, Nyrén O, Johansson J-E, Gridley G, McLaughlin JK, Adami H-O, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer. 2003;98:1727–34.CrossRef PubMed
  4.Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2013;10:49–54.CrossRef PubMed
  5.White CP. On the occurrence of crystals in tumours. J Pathol Bacteriol. 1909;13:3–10.CrossRef
  6.Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010;21:61–8.PubMedCentral CrossRef PubMed
  7.Breau RH, Karnes RJ, Jacobson DJ, McGree ME, Jacobsen SJ, Nehra A, et al. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol. 2010;184:494–9.PubMedCentral CrossRef PubMed
  8.Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer. 2011;47:819–30.CrossRef PubMed
  9.Lee SH, Park TJ, Bae MH, Choi SH, Cho YS, Joo KJ, et al. Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia. Korean J Urol. 2013;54:750–5.PubMedCentral CrossRef PubMed
  10.Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342:1094–8.PubMedCentral CrossRef PubMed
  11.Hirayama T, Mizokami Y, Honda A, Homma Y, Ikegami T, Saito Y, et al. Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level. Hepatol Res. 2009;39:149–56.CrossRef PubMed
  12.Umetani M, Shaul PW. 27-Hydroxycholesterol: the first identified endogenous SERM. Trends Endocrinol Metab. 2011;22:130–5.PubMedCentral CrossRef PubMed
  13.DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP. 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. 2008;22:65–77.PubMedCentral CrossRef PubMed
  14.Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, et al. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001;276:38378–87.CrossRef PubMed
  15.Cruz P, Torres C, Ramírez ME, Epuñán MJ, Valladares LE, Sierralta WD. Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol. Exp Ther Med. 2010;1:531–6.PubMedCentral PubMed
  16.Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 2013;5:637–45.PubMedCentral CrossRef PubMed
  17.Horie-Inoue K, Bono H, Okazaki Y, Inoue S. Identification and functional analysis of consensus androgen response elements in human prostate cancer cells. Biochem Biophys Res Commun. 2004;325:1312–7.CrossRef PubMed
  18.Nelson ER, DuSell CD, Wang X, Howe MK, Evans G, Michalek RD, et al. The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors. Endocrinology. 2011;152:4691–705.PubMedCentral CrossRef PubMed
  19.Ma D, Liu W, Wang Y. ApoA-I or ABCA1 expression suppresses fatty acid synthesis by reducing 27-hydroxycholesterol levels. Biochimie. 2014;103:101–8.CrossRef PubMed
  20.Burkard I, von Eckardstein A, Waeber G, Vollenweider P, Rentsch KM. Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis. 2007;194:71–8.CrossRef PubMed
  21.Dzeletovic S, Breuer O, Lund E, Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem. 1995;225:73–80.CrossRef PubMed
  22.Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007;13:1185–92.CrossRef PubMed
  23.DuSell CD, Nelson ER, Wang X, Abdo J, Mödder UI, Umetani M, et al. The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology. 2010;151:3675–85.PubMedCentral CrossRef PubMed
  24.Marwarha G, Ghribi O. Does the oxysterol 27-hydroxycholesterol underlie Alzheimer’s disease-Parkinson’s disease overlap? Exp Gerontol. 2015;68:13–8.CrossRef PubMed
  25.Brown AJ, Jessup W. Oxysterols and atherosclerosis. Atherosclerosis. 1999;142:1–28.CrossRef PubMed
  26.Schüle R, Siddique T, Deng H-X, Yang Y, Donkervoort S, Hansson M, et al. Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis. J Lipid Res. 2010;51:819–23.PubMedCentral CrossRef PubMed
  27.Meaney S, Lütjohann D, Diczfalusy U, Björkhem I. Formation of oxysterols from different pools of cholesterol as studied by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice. Biochim Biophys Acta. 2000;1486:293–8.CrossRef PubMed
  28.Meaney S, Hassan M, Sakinis A, Lütjohann D, von Bergmann K, Wennmalm A, et al. Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. J Lipid Res. 2001;42:70–8.PubMed
  29.Ramirez DMO, Andersson S, Russell DW. Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J Comp Neurol. 2008;507:1676–93.PubMedCentral CrossRef PubMed
  30.Bandaru VVR, Haughey NJ. Quantitative detection of free 24S-hydroxycholesterol, and 27-hydroxycholesterol from human serum. BMC Neurosci. 2014;15:137.PubMedCentral CrossRef PubMed
  31.Cruz P, Epuñán MJ, Ramírez ME, Torres CG, Valladares LE, Sierralta WD. 27-hydroxycholesterol and the expression of three estrogen-sensitive proteins in MCF7 cells. Oncol Rep. 2012;28:992–8.PubMed
  32.Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308.CrossRef PubMed
  33.Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011;10:20.PubMedCentral CrossRef PubMed
  34.Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009;10:981–91.PubMedCentral CrossRef PubMed
  35.Lu T, Lin W-J, Izumi K, Wang X, Xu D, Fang L-Y, et al. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol. 2012;26:1707–15.PubMedCentral CrossRef PubMed
  36.Izumi K, Mizokami A, Lin W-J, Lai K-P, Chang C. Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 2013;182:1942–9.PubMedCentral CrossRef PubMed
  37.Saxena P, Trerotola M, Wang T, Li J, Sayeed A, Vanoudenhove J, et al. PSA regulates androgen receptor expression in prostate cancer cells. Prostate. 2012;72:769–76.PubMedCentral CrossRef PubMed
  38.Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004;93:233–41.CrossRef PubMed
  39.Hipfner DR, Cohen SM. Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol. 2004;5:805–15.CrossRef PubMed
  40.Mhaidat NM, Thorne RF, Zhang XD, Hersey P. Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Mol Cancer Res. 2007;5:1073–81.CrossRef PubMed
  41.Petrylak DP. The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol. 2006;8(Suppl 2):S48–55.PubMedCentral PubMed
  42.Kellokumpu-Lehtinen P-L, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14:117–24.CrossRef PubMed
  43.McKeage K, Keam SJ. Docetaxel in hormone-refractory metastatic prostate cancer. Drugs. 2005;65:2287–94 (discussion 2295–7).CrossRef PubMed
  44.Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, et al. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer. 2015;14:122.PubMedCentral CrossRef PubMed
  
• 作者单位：Shaneabbas Raza (1)
  Megan Meyer (1)
  Jared Schommer (1)
  Kimberly D. P. Hammer (2)
  Bin Guo (3)
  Othman Ghribi (1)
  
  1. Department of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, 501 North Columbia Road, Grand Forks, ND, 58202, USA
  2. Department of Veteran Affairs, Fargo VA Health Care System, Fargo, ND, 58102, USA
  3. Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, 58108, USA
  
• 刊物主题：Oncology; Hematology; Pathology; Internal Medicine;
• 出版者：Springer US
• ISSN：1559-131X

文摘

Although the causes of prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are not known, the role of oxidative stress, aging, and diet are suspected to increase the incidence of prostate complications. The cholesterol oxidation derivative (oxysterol) 27-hydroxycholesterol (27-OHC) is the most prevalent cholesterol metabolite in the blood. As aging, oxidative stress, and hypercholesterolemia are associated with increased risk of PCa and BPH, and because 27-OHC levels are also increased with aging, hypercholesterolemia, and oxidative stress, determining the role of 27-OHC in the progression of PCas and BPH is warranted. In this study, we determined the effect of 27-OHC in human prostate epithelial cells RWPE-1. We found that 27-OHC stimulates proliferation and increases androgen receptor (AR) transcriptional activity. 27-OHC also increased prostate-specific antigen expression and enhanced AR binding to the androgen response element compared to controls. Silencing AR expression with siRNA markedly reduced the 27-OHC-induced proliferation. Furthermore, 27-OHC blocked docetaxel-induced apoptosis. Altogether, our results suggest that 27-OHC may play an important role in PCa and BPH progression by promoting proliferation and suppressing apoptosis.